GlobalData on MSN

Gilead Sciences to acquire Repare’s RP-3467

Gilead will pay Repare $25m upfront, and up to an additional $5m upon completion of certain technology transfer activities.
Nasdaq

Repare Therapeutics Sells Polymerase Theta ATPase Inhibitor To Gilead For Up To $30Mln

(RTTNews) - Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, has entered into a definitive agreement with Gilead Sciences, Inc. (GILD) for the acquisition of its ...

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to ...
Baylor College of Medicine

TFEB and V-ATPase-mediated Lysosomal Stress Sensing Pathway in Tauopathy

Early work revealed that TFEB is highly effective in ameliorating tau/NFT pathology and rescuing cognitive impairment and neurodegeneration. TFEB targets only the aberrant tau species and this ...
Morningstar

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration Repare Therapeutics Inc. (“Repare” or the “Company”) ...